WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 05/11/22

China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...

WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability PR Newswire -   WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests i...

The ADRs of Shanghai-based I-Mab (NASDAQ:IMAB) jumped ~18% in the pre-market Wednesday after Bloomberg reported that the clinical-stage biotech company was considering options including a potential sale amid takeover interest from other global drugmakers. I-Mab (IMAB) has lost more ...

Wuxi Biologics ADR press release (OTCPK:WXXWY): FY Non-GAAP EPS of RMB0.75. Revenue of RMB10.29B (+83.4% Y/Y). By the end of 2021, the Group's total backlog increased to $13,597M, up 20.1% Y/Y.  The Group is still aiming at achieving free cash flow positive in 2022. To meet growing deman...

On Feb. 15, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q4 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of December 2021. This list is particularly ti...

U.S.-listed Chinese biotech companies are trading lower after the U.S. commerce department added life-sciences company, WuXi Biologics (OTCPK:WXXWY -13.5%) (OTCPK:WXIBF -22.6%), to its “unverified” list for exporters. Notable decliners include I-Mab (IMAB -5.7%) and BeiGene (BGN...

WuXi Biologics (Cayman) (OTCPK:WXXWY) said the company has become aware of a recent U.S. Commerce Department announcement that two of its subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on Feb. 8. The company said the reason for this actio...

WuXi Biologics Statement PR Newswire SHANGHAI , Feb. 7, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unveri...

WuXi Biologics (OTCPK:WXXWY) and South Korea based ImmuneOncia Therapeutics announce that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47. Wit...

UBS highlights its picks in its four next-big-thing sectors: Greentech, 5G+, Fintech and Healthtech. "While this is a longer-term focus, we see attractive investment opportunities in the short to medium term whereby companies benefit from significant fiscal spending following the pandemic as ...